author = {Dave, Vivek. and Pathengay, Avinash. and Behera, Shashwat. and Joseph, Joveeta. and Sharma, Savitri. and Pappuru, Rajeev. and Das, Taraprasad.}, title = {{Enterobacter endophthalmitis: Clinical settings, susceptibility profile, and management outcomes across two decades}}, journal ={Indian Journal of Ophthalmology}, volume ={68}, number ={1}, pages = {112-116}, doi = {10.4103/ijo.IJO_693_19}, year = {2020}, abstract ={ Purpose: To describe the clinical presentation and management of Enterobacter endophthalmitis and compare with previous in-house published literature. Methods: This was a retrospective interventional comparative case series involving 44 cases with culture proven Enterobacter endophthalmitis from April 2006 to August 2018 who underwent vitrectomy/vitreous biopsy, intravitreal antibiotics with or without additional procedures as appropriate. The current outcomes were compared to the outcomes previously reported a decade back from our center. The mean age at presentation, predisposing factor, number of interventions, interval between inciting event and presentation, type of intravitreal antibiotic used, anatomic, and the functional outcomes were analyzed and compared to the previous series. Results: There were 30 males. Mean age was 22.73 ± 21.35 years (median 14 years). Inciting event was open globe injury in 34 (77.27%) eyes, 4 (9.09%) eyes following cataract surgery, 3 (6.81%) eyes with endogenous endophthalmitis, 2 (4.54%) eyes following keratoplasty, and 1 eye (2.27%) following trabeculectomy. Presenting visual acuity was favorable (≥20/400) in 2 eyes (4.54%), at the final visit it was in 11 eyes (25%). The organisms were most sensitive to ciprofloxacin (95.12%), amikacin (90.47%), and ceftazidime (85.36%). A comparison of the current study with previous in-house study showed that number of eyes with presenting vision ≥20/400 as well as final vision ≥20/400 were comparable. Susceptibility was highest to ciprofloxacin 39 (95.12%) (previous series) and 33 (92%) (current series). Conclusion: Enterobacter organisms show susceptibility to ciprofloxacin, amikacin, and ceftazidime. Susceptibility profile, clinical presentations, and management remain largely similar over many years. Final outcome is unfavorable. }, URL ={https://journals.lww.com/ijo/pages/default.aspx/article.asp?issn=0301-4738;year=2020;volume=68;issue=1;spage=112;epage=116;aulast=Dave;t=6}, eprint ={https://journals.lww.com/ijo/pages/default.aspx/article.asp?issn=0301-4738;year=2020;volume=68;issue=1;spage=112;epage=116;aulast=Dave;t=6} }